Joachim Kiemle-Kallee

This panel will examine how aligning target biology, mechanism of action, and bispecific format is critical to therapeutic success. Experts will explore strategies for selecting and validating novel targets, addressing tumor heterogeneity, and optimizing design parameters to enhance efficacy while managing safety.

• How do you determine whether a target’s biology aligns with the intended mechanism of action of your bispecific construct?
• What are the key molecular design considerations? Looking at considerations, such as affinity, format, and valency for a selected target
• How can we better predict and manage unexpected biology that arises from targeting a molecule in a specific disease context?
• What approaches are most effective for validating novel targets, particularly in solid tumors with heterogeneous expression?
• How do different bispecific modalities (e.g., T-cell engagers, costimulatory bispecifics, ADCs) influence target selection strategy?
• How do you balance the therapeutic window by assessing target expression across tumor versus normal tissue to mitigate toxicity?